Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsConstruction in ProgressCurrent AssetsCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Current Taxes (2017 - 2026)

Dr Reddys Laboratories has reported Current Taxes over the past 10 years, most recently at $47.1 million for Q1 2026.

  • For Q1 2026, Current Taxes rose 34.83% year-over-year to $47.1 million; the TTM value through Mar 2026 reached $47.1 million, up 34.83%, while the annual FY2026 figure was $47.1 million, 34.71% up from the prior year.
  • Current Taxes for Q1 2026 was $47.1 million at Dr Reddys Laboratories, up from $35.0 million in the prior quarter.
  • Over five years, Current Taxes peaked at $47.1 million in Q1 2026 and troughed at $21.5 million in Q1 2022.
  • A 5-year average of $31.6 million and a median of $28.2 million in 2024 define the central range for Current Taxes.
  • Biggest five-year swings in Current Taxes: increased 8.13% in 2024 and later skyrocketed 34.83% in 2026.
  • Year by year, Current Taxes stood at $21.5 million in 2022, then increased by 21.43% to $26.1 million in 2023, then increased by 8.13% to $28.2 million in 2024, then grew by 23.99% to $35.0 million in 2025, then skyrocketed by 34.83% to $47.1 million in 2026.
  • Business Quant data shows Current Taxes for RDY at $47.1 million in Q1 2026, $35.0 million in Q1 2025, and $28.2 million in Q1 2024.